Physician profile
Robert E Vlach
NPI 1124027610
$499.35
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $123 · 2021: $190 · 2022: $59.16.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $119.04 | 2021 | |
| Neotract INC. | $111.24 | 2019-2020 | |
| Myovant Sciences INC. | $91.39 | 2021-2022 | |
| Boston Scientific Corporation | $28.18 | 2019 | |
| Astellas Pharma US INC | $25.55 | 2019-2020 | |
| Palette Life Sciences, INC. | $24.21 | 2022 | |
| Allergan, INC. | $23.41 | 2019 | |
| Endo Pharmaceuticals INC. | $18.86 | 2019 | |
| Janssen Biotech, INC. | $14.55 | 2019 | |
| Coloplast Corp | $14.39 | 2022 | |
| Pfizer INC. | $14.30 | 2020 | |
| Blue Earth Diagnostics | $14.23 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Vlach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.